-
Assessing the Fiscal Burden of Obesity Using a Public Economic Framework
-
Are Clinical Outcome Assessments Sufficiently Valued?
-
The Global Socioeconomic Impact of Rare Diseases: A Call for Action
-
Revolutionizing Systematic Reviews: Harnessing the Power of AI
-
May 5: Estimating Health-State Utility for Economic Models in Clinical Trials and Real-World Studies- In Person at ISPOR 2024
-
May 5: Valuation of Innovative Drugs- In Person at ISPOR 2024
-
May 5: Handling Uncertainty in Health Technology Assessment Processes- In Person at ISPOR 2024
-
May 5: Valuing Health: The Generalized Risk Adjusted Cost-Effectiveness (GRACE) Model- In Person at ISPOR 2024
-
May 5: Causal Inference and Causal Diagrams in Big, Real-World Observational Data and Pragmatic Trials- In Person at ISPOR 2024
-
May 5: Network Meta-Analysis in Relative Effectiveness Research- In Person at ISPOR 2024
-
May 5: Applied Cost-Effectiveness Modeling with R- In Person at ISPOR 2024
-
May 5: A Health Economics Approach to US Value Assessment Frameworks- In Person at ISPOR 2024
-
May 5: Advanced Patient-Reported Outcomes- In Person at ISPOR 2024
-
May 5: Developing Decision-Grade Real-World Evidence- In Person at ISPOR 2024
-
May 5: Introduction to Machine Learning Methods- In Person at ISPOR 2024
-
May 5: Introduction to Health Technology Assessment- In Person at ISPOR 2024
-
April 17-18: Learning and Applying Discrete Event Simulation- Virtual
-
Revolutionizing Clinical Trials: Harnessing Real-World Evidence to Drive Diversity and Clinical Implementation
-
April 10-11: Budget Impact Analysis I: A 6-Step Approach- Virtual
-
Measuring the Indirect Costs Driving Financial Toxicity in Oncology